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Abstract
Background: Despite much effort on the treatment of breast cancer over the decades, a great uncertainty
regarding the appropriate molecular biomarkers and optimal therapeutic strategy still exists. This research was
performed to analyze the association of SPAG5 gene expression with clinicopathological factors and survival
outcomes.
Methods: We used a breast cancer database including 5667 patients with a mean follow-up of 69 months.
Kaplan-Meier survival analyses for relapse free survival (RFS), overall survival (OS), and distant metastasis-free
survival (DMFS) were performed. In addition, ROC analysis was performed to validate SPAG5 as a prognostic
candidate gene.
Results: Mean SPAG5 expression value was significantly higher with some clinicopathological factors that resulted in
tumor promotion and progression, including poor differentiated type, HER2 positive or TP53 mutated breast cancer.
Based on ROC-analysis SPAG 5 is a suitable prognostic marker of poor survival. In patients who received chemotherapy
alone, SPAG5 had only a moderate and not significant predictive impact on survival outcomes. However, in hormonal
therapy, high SPAG5 expression could strongly predict prognosis with detrimental RFS (HR = 1.57, 95% CI 1.2–2.06, p =
0.001), OS (HR = 2, 95% CI 1.05–3.8, p = 0.03) and DMFS (HR = 2.36, 95% CI 1.57–3.54, p < 0.001), respectively. In
addition, SPAG5 could only serve as a survival predictor in ER+, but not ER- breast cancer patients. Patients might
also be at an increased risk of relapse despite being diagnosed with a lower grade cancer (well differentiated type).
Conclusions: SPAG5 could be used as an independent prognostic and predictive biomarker that might have clinical
utility, especially in ER+ breast cancer patients who received hormonal therapy.
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Background
Breast cancer is one of the leading types of cancer in
women which accounted for about 39,620 deaths among
US women in 2013 [1]. Despite much effort on the treat-
ment of breast cancer over the decades, a great uncer-
tainty regarding the optimal therapeutic strategy,
especially effective precision medicine for breast cancer
still exists [2]. As only those individuals who harbor the
appropriate molecular biomarkers are eligible for
effective precision treatment [3], identification, stratifica-
tion and evaluation of better prognostic/predictive
markers are in great need [4]. Nowadays, breast cancer
systemic treatment strategies are guided by molecular
subtypes based on estrogen receptor (ER), progesterone
receptor (PR) and epidermal growth factor receptor 2
(HER2) statuses [5], and clinically useful biomarkers are
demanded in predicting a patient’s response and long-
term outcomes. Some potential indicators have been
found in the diagnosis and therapeutic monitoring of
patients with breast cancer, such as SASH1, cystatin C
and activin A [6–8].
Sperm-associated antigen 5 (SPAG5, also named DEE-
PEST, MAP126 or hMAP126), located on chromosome
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17q11.2, was up-regulated in M-phase cells and played a
vital role in cell mitosis and cell cycle checkpoint regula-
tion [9]. By binding to microtubules, it regulated the
timing of spindle organization as well as separation of
sister chromatids [10]. In addition, SPAG5 protected
cells from apoptosis via the mTOR signaling pathway [9,
11]. Knockdown of SPAG5 could significantly suppress
proliferation and invasion of prostate cancer cells
in vitro, along with inhibiting the growth and metastasis
of tumor in vivo [10].
Previous studies indicated that the overexpression of
SPAG5 gene might act as a potential biomarker which
predicted poor prognosis in patients with lung cancer
and cervical cancer [11, 12]. However, few studies fo-
cused on the prognostic value of SPAG5 in breast cancer
patients. A recent study [13] reported that the transcript
and protein products of SPAG5 might be independent
prognostic and predictive biomarkers for chemotherapy
sensitivity, particularly in ER negative (ER-) breast can-
cer. One stated the prognostic association of SPAG5 in
ER+ breast cancer [14]. In addition, SPAG5 module was
found to be involved in the mitotic checkpoint and asso-
ciated with proliferation and progression of male breast
cancer (MBC) [15].
To comprehensively assess the association of SPAG5
gene expression with clinical outcomes in patients with
different breast cancer subtypes, including those under-
going systematic treatment (endocrine therapy and/or
chemotherapy), we used a large public database contain-
ing pure transcriptomic data of more than 5000 breast
cancer patients and validated SPAG5 as a prognostic
candidate gene.
Methods
Breast cancer microarray database
Kaplan–Meier Plotter (http://www.kmplot.com) is an
online public database evaluating the effect of 54,675
genes on patient clinical outcomes, using 10,293 samples
of lung, breast, gastric or ovarian cancers. This online
tool is handled by a PostgreSQL server that could simul-
taneously integrate gene expression and clinical data [16,
17]. Gene expression data and the survival information
are derived from the Gene Expression Omnibus (GEO),
The Cancer Genome Atlas (TCGA) and European
Genome-phenome Atlas (EGA) (see Additional file 3:
Table S1).
Data retrieval
We performed data retrieval from the online tool from
July 2016 to October 2016. The database contained in-
formation of 5667 patients with breast cancer, with a
median follow-up of 69 months. It allowed for filtering
by ER, PR and HER2 statuses, lymph node statuses
(positive or negative), grade (I, II or III) and TP53
statuses (mutated or wild type) [18]. In addition, analyses
could be restricted to cohorts that only included patients
with endocrine treatment or chemotherapy. Biased ar-
rays were excluded. Although not all clinic-pathological
data and survival outcomes were obtainable in each pa-
tient, we reported all available data.
Statistical analysis
We compared SPAG5 gene expression level using
Kruskal-Wallis test (multi-group comparisons) or Mann-
Whitney U test (two-cohort comparison). Mean expres-
sion value, 95% Confidence Interval (CI), standard error
and standard deviation were analyzed. For the prognos-
tic value of gene SPAG5, we plotted the Kaplan–Meier
curves for SPAG5 (Affymetrix ID: 203145_at) in different
breast cancer subtypes. The cutoff value of gene expres-
sion was chosen as median which split the patient sam-
ples into two groups and plots generated accordingly.
The two patient cohorts were then compared, and we
performed univariate Cox regression to calculate the
hazard ratio (HR) with 95% confidence intervals (CIs)
and log rank P-value. As not every patient’s data was
included in the database that we needed to perform mul-
tiple Cox regression analyses, it was the best to do the
multiple hypothesis testing [19, 20].
In addition, ROC analysis was performed by splitting
the population into good and poor-outcome based on
RFS, and we checked whether SPAG5 expression recog-
nizes poor/good survival. We run the analysis for RFS of
the entire dataset, ER-positive population and ER-
positive population treated with endocrine therapy at 5
years and 10 years, respectively. Evaluation of gene
SPAG5 with relapse free survival (RFS), overall survival
(OS) and distant metastasis-free survival (DMFS) was
performed. We also used this Kaplan-Meier Plotter to
stratify breast cancer patient microarray data by ER, PR,
HER2, lymph node status, histological grade and TP53
status, and explored the prognostic value of SPAG5 in
those different breast cancer subtypes. We explored the
survival of patients with different treatment strategies
(hormonal therapy and/or chemotherapy). P-value < 0.05
was considered to be a statistically significant difference.
Results
SPAG5 gene expression in breast cancer patients
The Kaplan–Meier Plotter surveyed public microarray
data repositories for survival among 5667 patients with
breast cancer. Mean SPAG5 expression value was higher
in ER- than ER+ breast cancer patients (mean value
434.48 vs. 602.64, p < 0.001), similar trend was also ob-
served in PR- and HER2+ breast cancer patients. In
addition, SPAG5 expression was progressively higher in
more aggressive grades/subtypes of the disease (see
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Additional file 3: Tables S2 and S3 and Additional file 1:
Figure S1).
SPAG5 gene expression was associated with breast cancer
progression and poor prognosis
We plotted the Kaplan-Meier survival curves for SPAG5
using the web-based curator. The results showed that
higher expression of SPAG5 was associated with worse
RFS (n = 3557, HR = 1.72, 95% CI 1.54–1.94, p < 0.001),
OS (n = 1117, HR = 1.86, 95% CI 1.46–2.37, p < 0.001),
and DMFS (n = 1610, HR = 1.88, 95% CI 1.53–2.32, p <
0.001) in patients with breast cancer. Table 1 and Fig. 1
present the prognostic effect of the expression of
SPAG5. In addition, we compared and correlated SPAG5
with other markers of progression, such as p53, AURKA,
MKI67 and BIRC5, to assess independent value, and
results showed that similar to AURKA, MKI67, BUB1,
TOP2A which had statistically significant results for
RFS, SPAG5 was associated with breast cancer progres-
sion. There was a significant association (coefficient over
0.25, p < 0.001) of SPAG5 with TOP2A, BIRC5, AURKA
and BUB1. The association with PCNA and TP53 was
significant, but the effect was too small to be meaningful
(Additional file 3: Table S4). Based on ROC analysis,
SPAG5 is a suitable prognostic marker of poor survival
(see Fig. 2).
The expression of gene SPAG5 in patients receiving
systematic therapy
In patients with endocrine therapy, low SPAG5 tran-
script expression was significantly associated with longer
RFS (HR = 1.57, 95% CI 1.2–2.06, p = 0.001) and OS (HR
2, 95% CI 1.05–3.8, p = 0.03) than was high SPAG5
expression. However, in patients who received chemo-
therapy, no significant difference existed between low
and high SPAG5 transcript expressions in RFS (HR =
Table 1 PH Cox regression univariate analyses for the association of gene SPAG5 with cancer progression and prognosis in different
breast cancer subtypes
Breast cancer
subtypes
RFS OS DMFS
n HR P-value n HR P-value n HR P-value
Total 3557 1.72 (1.54–1.94) < 0.001 1117 1.86 (1.46–2.37) < 0.001 1610 1.88 (1.53–2.32) < 0.001
ER status
ER+ 2766 1.77 (1.55–2.03) < 0.001 377 2.74 (1.74–4.33) < 0.001 577 2.89 (1.95–4.29) < 0.001
ER- 788 1.03 (0.82–1.28) 0.81 142 0.91 (0.52–1.6) 0.74 170 1.04 (0.62–1.73) 0.89
PR status
PR+ 525 2.02 (1.38–2.94) < 0.001 0 – – 122 1.35 (0.41–4.46) 0.62
PR- 483 1.42 (1.04–1.93) 0.027 2 – – 95 2.24 (1.04–4.85) 0.035
HER2 status
HER2+ 168 0.78 (0.46–1.32) 0.36 28 0.59 (0.19–1.83) 0.36 66 1.54 (0.61–3.91) 0.36
HER2- 756 1.78 (1.36–2.34) < 0.001 62 0.92 (0.32–2.62) 0.87 82 2.43 (0.63–9.39) 0.18
ER+/PR+/HER2+ 76 1.53 (0.33–7.09) 0.58 36 3.54 (0.41–30.58) 0.22 45 1.83 (0.36–9.47) 0.46
ER+/PR−/HER2+ 26 0.47 (0.09–2.35) 0.35 – – – – – –
ER+/PR+/HER2- 339 2.41 (1.48–3.93) < 0.001 39 2.04 (0.18–22.51) 0.55 79 1.66 (0.33–8.22) 0.53
ER+/PR−/HER2- 77 1.47 (0.65–3.33) 0.35 – – – – – –
ER−/PR−/HER2- 255 1.45 (0.9–2.34) 0.13 – – – 43 3.33 (0.67–16.58) 0.12
LN status
LN+ 945 1.63 (1.3–2.03) < 0.001 197 1.38 (0.84–2.28) 0.2 337 1.74 (1.14–2.65) 0.009
LN- 1813 1.67 (1.4–1.99) < 0.001 425 2.41 (1.56–3.74) < 0.001 896 2.42 (1.79–3.27) < 0.001
Grade
1 308 2.52 (1.4–4.54) 0.0014 135 2.45 (0.86–6.96) 0.083 172 2.35 (0.94–5.84) 0.059
2 724 1.9 (1.45–2.49) < 0.001 287 2.92 (1.76–4.86) < 0.001 495 1.93 (1.34–2.78) < 0.001
3 723 1.17 (0.91–1.51) 0.23 347 0.9 (0.6–1.34) 0.6 391 1.12 (0.77–1.64) 0.54
TP53 status
Mutated 188 0.91 (0.57–1.47) 0.71 111 0.95 (0.45–2.04) 0.91 83 0.8 (0.33–1.93) 0.62
Wild type 273 1.49 (0.97–2.28) 0.064 187 2.16 (1.1–4.23) 0.022 109 3.44 (1.44–8.22) 0.0031
RFS Relapse free survival, OS Overall survival, DMFS Distant metastasis-free survival, HR Hazard ratio, − Ddata not available, LN Lymph node
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1.1, 95% CI 0.74–1.63, p = 0.64) and OS (HR = 1.54, 95%
CI 0.74–3.2, p = 0.25) of breast cancer patients. Similar
results were also seen for DMFS in patients with endo-
crine therapy (HR = 2.36, 95% CI 1. 57–3.54, p < 0.001)
and chemotherapy (HR = 1.49, 95% CI 0.65–3.4, p =
0.34) (see Table 2 and Fig. 3). Tamoxifen was the most
common drug used in hormonal therapy, and in patients
receiving tamoxifen-only therapy, SPAG5 overexpression
was associated with decreased RFS (HR = 1.57, 95% CI
1.17–2.12, p = 0.0027), OS (HR = 2.13, 95% CI 1.00–4.52,
p = 0.044) and DMFS (HR = 2.23, 95% CI 1.52–3.26, p <
0.001). In 171 patients receiving both hormonal therapy
and chemotherapy, SPAG5 overexpression was associ-
ated with decreased RFS (HR = 2.77, 95% CI 1.37–5.6,
p = 0.0032) and data for OS and DMFS among those
patients were not enough to draw a concrete conclusion
(see Table 2 and Fig. 3).
In multiple hypothesis testing, the association
remained significant in patients with endocrine therapy
with poor RFS (HR = 1.61, 95% CI 1.26–2.04, p < 0.001)
and OS (HR = 1.95, 95% CI 1.47–2.60, p < 0.001). Data
for DMFS and tamoxifen-only therapy was not enough
for multivariate analysis (Table 3 and Fig. 4).
The prognostic value of SPAG5 expression in breast
cancer with different molecular subtypes, histological
grades and TP53 statuses
When patients were differentiated based on ER expres-
sion statuses, we plotted RFS, OS and DMFS curves for
the ER+ and ER- subsets. We observed that high SPAG5
Fig. 1 The prognostic effect of the expression of SPAG5 in www.kmplot.com. a RFS b OS c DMFS
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expression was associated with a significant increase in
risk of relapse among ER+ (HR = 1.77, 95% CI 1.55–2.03,
p < 0.001), but not ER- breast cancer patients (HR = 1.03,
95% CI 0.82–1.28, p = 0.81). Similarly, SPAG5 gain or
amplification was associated with shorter OS (HR = 2.74,
95% CI 1.74–4.33, p < 0.001) and DMFS (HR = 2.89, 95%
CI 1.95–4.29, p < 0.001) in the ER+ subgroup, but not
ER- subgroup (p = 0.74 and p = 0.89, respectively) (see
Table 1 and Additional file 2: Figure S2). Likewise, in
multiple hypothesis testing, higher expression of SPAG5
was not associated with poorer survival in ER- subgroup,
but the association was significant in ER+ patients with
a reduction in RFS (HR = 1.85), OS (HR = 2.61) and
DMFS (HR = 2.92) (see Table 4). In ER+/PR+/HER2-
subgroup, SPAG5 expression was associated with shorter
RFS (HR = 2.41, 95% CI 1.48–3.93, p < 0.001) (see Table 1).
We further stratified ER+ patients according to PR,
HER2, lymph node status, histological grade and TP53
statuses and the results were listed in Additional file 3:
Table S5.
Among patients with grade 1 breast cancer, high
SPAG5 expression was associated with a great increase
Fig. 2 ROC analysis was performed by splitting the population into good and poor-outcome based on RFS, the analysis was run for RFS of the
entire dataset, ER+ population and ER+ population treated with endocrine therapy at 5 years and 10 years, respectively
Table 2 PH Cox regression univariate analyses for the association of gene SPAG5 with endocrine therapy and chemotherapy
RFS OS DMFS
n HR P-value n HR P-value n HR P-value
Systemic therapy subtypes
Endo 849 1.57 (1.2–2.06) 0.001 128 2 (1.05–3.8) 0.03 513 2.36 (1.57–3.54) < 0.001
Tamoxifen-only 739 1.57 (1.17–2.12) 0.0027 114 2.13 (1–4.52) 0.044 556 2.23 (1.52–3.26) < 0.001
Chemo 274 1.1 (0.74–1.63) 0.64 69 1.54 (0.74–3.2) 0.25 65 1.49 (0.65–3.4) 0.34
Endo + chemo 171 2.77 (1.37–5.6) 0.0032 34 4.28 (0.48–38.33) 0.16 86 1.96 (0.66–5.86) 0.22
Endo Endocrine therapy, chemo Chemotherapy
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in risk of recurrence (HR = 2.52, 95% CI 1.4–4.54, p =
0.0014). In more advanced cancers, high expression of
SPAG5 indicated less of an association with RFS in grade
2 cancer (HR = 1.9, 95% CI 1.45–2.49, p < 0.001), and
only a moderate tendency with no statistical difference
toward shorter RFS was seen among patients with grade
3 cancer (HR = 1.17, 95% CI 0.91–1.51, p = 0.23) (see
Table 1 and Fig. 5). In TP53 wild-type breast carcin-
omas, RFS (HR = 1.49, 95% CI 0.97–2.28, p = 0.064), OS
(HR = 2.16, 95% CI 1.1–4.23, p = 0.022) and DMFS
(HR = 3.44, 95% CI 1.44–8.22, p = 0.0031) were better in
patients with low-expressed SPAG5, however, the sur-
vival curves did not show a significant difference in RFS
of TP53-mutated breast cancer patients (p = 0.71). RFS
was low in HER2- patients (HR = 1.78, 95% CI 1.36–
2.34, p < 0.001), but this prognostic association was not
obvious in HER2+ patients (HR = 0.78, 95% CI 0.46–
1.32, p = 0.36). Results of SPAG5 expression in different
PR statuses and lymph node statuses were also exhibited
in Table 1. Multiple hypothesis testing supported the
prognostic association of SPAG5 in these different sub-
groups of patients (see Table 4).
Fig. 3 SPAG5 in patients with systematic therapy in univariate analysis. a. Association of SPAG5 with survival outcomes in patients with endocrine
therapy. b. Association of SPAG5 with survival outcomes in patients with chemotherapy. c. SPAG5 expression was predictive of relapse in patients
with tamoxifen-only therapy. d. SPAG5 expression and survival outcomes in patients with both endocrine therapy and chemotherapy
Table 3 Multiple hypothesis testing of the association of gene SPAG5 with endocrine therapy and chemotherapy
RFS OS DMFS
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
Systemic therapy subtypes
Endocrine therapy 1.61 1.26–2.04 < 0.001 1.95 1.47–2.60 < 0.001 1.45 0.85–2.48 ns,0.17
Chemotherapy 1.54 1.21–1.98 < 0.001 1.57 1.16–2.12 0.0033 1.10 0.70–1.71 ns,0.68
Endo + chemo 1.69 1.02–2.82 ns,0.0428 1.67 1.01–2.80 ns,0.051 0.99 0.34–2.86 ns,0.988
ns Not significant after correction for multiple hypothesis testing, endo Endocrine therapy, chemo Chemotherapy
Zhu et al. BMC Cancer         (2019) 19:1046 Page 6 of 12
Discussion
In recent years, more and more attention has been
attached on precision medicine, and there is a growing
need for identification of prognostic biomarkers. SPAG5,
originally identified as a microtubule-associated protein,
with dual centrosome and kinetochores localization [21],
has been reported to act as a promoter in tumorigenesis
and progression [12]. In our study, data mining of 5667
publically available gene expression microarrays showed
that elevated SPAG5 expression in breast cancer pre-
dicted a poor prognosis by the Kaplan-Meier method.
We found that high SPAG5 expression was associated
with lower RFS, OS, and DMFS, and SPAG5 might act
as an important marker in systematic therapy, especially
in ER+ breast cancer patients who received hormonal
therapy.
SPAG5 was reported to be up-regulated in M-phase
cells and play a vital role in cell mitosis and cell cycle
checkpoint regulation [9]. In previous studies, SPAG5
was found increasing in many tumors and considered as
a predominant oncogene in tumor promotion and me-
tastasis [2]. Therefore, the identification of patients with
higher SPAG5 expression before treatment would be im-
portant for personalized treatment. In our study, using a
large combined cohort, we demonstrated that SPAG5
expression was significantly higher in patients with hor-
mone negative (ER- and PR-) breast cancer. Meanwhile,
we found that SPAG5 expression was increased in HER2
positive, poor differentiated, lymph node positive and
TP53 mutated breast cancer subtypes all of which were
strongly associated with tumor progression. Since the
oncogenic potential of SPAG5 was also reported in pros-
tate cancer [10], we hypothesized that SPAG5 could
serve as a marker in predicting breast cancer prolifera-
tion and progression.
Systemic therapy for patients with early-stage breast
cancer (ie, stages IA, IB, IIA, IIB, and IIIA) included
chemotherapy, endocrine therapy, and targeted therapy
[22]. It was important to choose certain biomarkers that
could predict response to therapy and clinical outcomes.
Recently a research team applied an artificial neural
network performing data mining functions on SPAG5
and found that SPAG5 expression products were inde-
pendent predictors for response to chemotherapy in
breast cancer [13]. Similarly, we found that SPAG5 could
predict prognosis of breast cancer patients with systemic
treatment. However, our results suggested that in
patients who received chemotherapy, SPAG5 had a mod-
erate impact on survival outcomes including RFS (HR =
1.1), OS (HR = 1.54) and DMFS (HR = 1.49) in univariate
Fig. 4 SPAG5 in patients with systematic therapy in multiple hypothesis testing. a Association of SPAG5 with survival outcomes in patients with
endocrine therapy. b Association of SPAG5 with survival outcomes in patients with chemotherapy. c SPAG5 expression and survival outcomes in
patients with both endocrine therapy and chemotherapy
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analysis and the survival curves did not show a signifi-
cant difference. As was referred in Hayes’s study [23], a
HR of less than 2 meant that the clinical value was un-
certain. A previous research suggested that SPAG5 could
affect chemotherapy sensitivity of taxol in cell lines [2].
The causes of the inconsistency might be attributed to
the different chemotherapy regimens and varying meth-
odological qualities.
Endocrine therapy abrogating estrogen dependent cell
proliferation has been shown to reduce recurrence and
death [24] for most patients with ER+ breast cancer.
Tamoxifen is a Selective Estrogen Receptor Modulator
(SERM) widely used for adjuvant therapy [25] and could
reduce 15-year risks of breast cancer recurrence and
mortality rates after surgery [26] in ER+ breast cancer
patients [27]. However, resistance to tamoxifen is fre-
quent, and patients receiving adjuvant tamoxifen may
eventually suffer recurrence or progression or even
death from metastases [28]. We found that when
patients received both hormonal therapy and chemo-
therapy, high SPAG5 expression could predict poor
prognosis with HRs for RFS, OS and DMFS of 2.77, 4.28
and 1.96, respectively, although for OS and DMFS the
difference was not statistically significant. Therefore, we
assumed that high SPAG5 expression in breast cancer
was potentially more relevant to malignant prognosis in
hormonal therapy. Further, in hormonal therapy only,
patients with high SPAG5 expression suffered decreased
RFS, OS and DMFS in both univariate and multiple hy-
pothesis testing. We considered that SPAG5 was corre-
lated with mTOR signaling pathway activity during
breast cancer treatment [2], and the cross-talk between
the estrogen receptor and mTOR signaling pathway, the
most well-known mechanism of endocrine resistance,
led to poor prognosis of patients [29]. Therefore, SPAG5
contributed to the development of hormonal therapy re-
sistance in ER+ breast cancer and the expression level
was predictive on the survival outcomes of patients
undergoing endocrine therapy. Further laboratory stud-
ies and clinical trials are needed to fully establish the
association of SPAG5 in endocrine and tamoxifen-based
therapy.
Choosing biomarkers based on different breast cancer
subtypes to predict survival is vital for both doctors and
patients. In clinical practice, ER, PR and HER2 statuses
are biologic markers considered to be crucial factors for
treatment [30]. In our study, the large cohort with 2766
samples proved apparent statistically significant differ-
ence between SPAG5-high and SPAG5-low expressions
in ER+, but not ER- breast cancer, meaning that the
Table 4 Multiple hypothesis testing of factors associated with survival
Breast cancer
subtypes
RFS OS DMFS
HR 95% CI P-value HR 95% CI P-value HR 95% CI P-value
ER status
ER+ 1.85 1.57–2.18 < 0.001 2.61 1.86–3.68 < 0.001 2.92 2.09–4.07 < 0.001
ER- 1.18 0.9–1.18 0.23 1.24 0.8–1.92 0.34 1.4 0.9–2.17 0.13
PR status
PR+ 3.4 2.09–5.55 < 0.001 6.34 1.26–31.88 ns, 0.011 3.92 1.15–13.32 ns, 0.018
PR- 1.51 1.11–2.05 ns, 0.0081 2.79 0.99–7.82 ns, 0.042 3.39 1.88–6.11 < 0.001
HER2 status
HER2+ 1.73 1.17–2.56 ns, 0.0053 3.42 1.52–7.72 0.0017 1.78 0.94–3.39 ns, 0.073
HER2- 2.12 1.79–2.51 < 0.001 1.7 1.37–2.12 < 0.001 1.93 1.58–2.36 < 0.001
Lymph node status
Lymph node+ 2.19 1.67–2.88 < 0.001 1.72 1.18–2.5 ns, 0.0044 2.03 1.4–2.94 < 0.001
Lymph node- 1.82 1.52–2.17 < 0.001 3 1.88–4.78 < 0.001 2.39 1.8–3.19 < 0.001
Grade
1 3.12 1.8–5.42 < 0.001 3.19 1.28–7.96 ns, 0.0087 2.79 1.23–6.33 ns, 0.011
2 1.99 1.56–2.55 < 0.001 2.55 1.67–3.89 < 0.001 2.61 1.85–3.68 < 0.001
3 1.35 1.07–1.7 ns, 0.011 1.25 0.89–1.77 0.19 1.75 1.13–2.73 ns, 0.012
TP53 status
Mutated 0.77 0.48–1.26 0.3 0.69 0.34–1.42 0.32 0.56 0.26–1.22 0.14
Wild type 1.82 1.16–2.85 ns, 0.0077 2.56 1.38–4.76 0.0021 3.67 1.76–7.63 < 0.001
ns Not significant after correction for multiple hypothesis testing; bold faced: remained significant
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expression level of SPAG5 could serve as a survival
predictor in ER+ rather than ER- breast cancer patients.
It might be because almost all ER+ patients received
hormonal therapy and SPAG5 expression predicted sur-
vival of patients in hormonal therapy. In some breast
cancer subtypes like PR+/ER+ breast cancer, positive
SPAG5 expression presented a strong trend toward
being associated with lower RFS (Additional file 3:
Table S5). Moreover, SPAG5 was an important determin-
ant of survival in HER2 negative rather than HER2 posi-
tive breast cancer patients.
Also in our study, RFS, OS and DMFS were better in
TP53 wild-type breast carcinomas patients with low-
expressed SPAG5, while the survival curves did not show
a significant difference in the survival outcomes of
TP53-mutated breast cancer patients. As mutations in
TP53 might lead to overexpression of SPAG5, which was
essential for promoting and regulating several aspects of
mitosis, such as inactivating Separase which maintained
the cohesion of sister chromatids, stabilizing mitotic
spindle, enhancing the fidelity of chromosome segrega-
tion, and silencing spindle assembly checkpoint [31],
G2/M phase transition and permanent cell cycling [32]
could be triggered. Studies have reported that mutant
TP53 was strongly associated with endocrine therapy
resistance and agents dramatically increasing wild-type
p53 levels could induce cell cycle arrest and apoptosis in
cancer cells [33]. All these were in accordance with our
Fig. 5 Expression of SPAG5 with RFS among A. all patients; B. ER+ breast cancer patients; C. ER- patients with grade 1–3 breast cancers
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hypothesis described previously that SPAG5 was related
to the development of hormone resistance in breast
cancer.
Histological grade is an important factor that affected
the prognosis in breast cancer. In our study, we found
that SPAG5 expression was not predictive in high grade
(poorly differentiated) breast cancer patients, perhaps
because poorly differentiated breast cancer cells prolifer-
ated fast and had a poor response to all kinds of therap-
ies including hormonal therapy [34]. On the contrary,
expression was strongly associated with survival out-
comes in low histological grade/proliferative status. As is
already known, SPAG5 is associated with cell cycle pro-
gression and formation of malignancies [10]. Consider-
ing the function of SPAG5 in progression of mitosis
[35], these results might imply that early in the etiology
of ER+ breast cancer subtypes, SPAG5 contributed to
disease progression [36]. The gradual loss of this effect
might be caused by the activation of parallel oncogenic
pathways [37], and therefore weakened the influence of
SPAG5 [38].
The potential of SPAG5 as a therapeutic target of
breast cancer has been highlighted in some experiments.
Down-regulation of SPAG5 exerted an antitumor effect.
A study indicated that when silencing the expression of
SPAG5 protein with RNA interference, multipolar and
highly disorganized spindles were formed, inducing
mitotic arrest [31] and apoptosis [39] through cell cycle
deregulation and mitotic catastrophe. In cervical cancer
cell lines, SPAG5 down-regulation resulted in inhibition
of cell growth and proliferation by inducing G2/M phase
cell cycle arrest [40]. What’s more, due to the loss of
microtubule-binding ability of SPAG5, suppression of
cell migration and invasion also occurred [41]. Thus, in
addition to a potential prognostic biomarker, SPAG5
might act as a therapeutic target for breast cancer.
To our knowledge, this is the largest up-to-date re-
search on the prognostic association of SPAG5 in differ-
ent subtypes of breast cancer. We analyzed different
subtypes of breast cancer comprehensively (including
poor differentiated type, HER2 positive or TP53 mutated
breast cancer), which was not reported previously. Our
work presented that for chemotherapy, the survival of
patients did not show a significant difference between
low and high SPAG5 transcript expressions, but the
prognostic association of SPAG5 in endocrine therapy
and tamoxifen-only therapy was explored. We offered
the potential to discriminate ER+ breast cancer patients
at higher risks of relapse, as well as providing opportun-
ities to customize therapies.
Our work has limitations. First, the molecular mechan-
ism and association of SPAG5 in tumorigenesis and pro-
gression have not yet been fully identified. Second, the
data of survival outcomes of new drugs for ER+ breast
cancers including palbociclib [42] were lacking. Third,
the optimal cutoff points of SPAG5 for survival predic-
tion in breast cancer patients still merit further investi-
gation. Therefore, further researches on the role of
SPAG5 in breast cancer are mandatory in the future.
Conclusions
In conclusion, as a progression-driving oncogene, SPAG5
was closely related to disease progression and malignant
prognosis of ER+ breast cancer patients undergoing endo-
crine therapy, and might act as a therapeutic target for
breast cancer.
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